Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
NewAmsterdam Pharma Co NV has a consensus price target of $30.75 based on the ratings of 10 analysts. The high is $47 issued by Scotiabank on December 11, 2024. The low is $19 issued by SVB Leerink on December 20, 2022. The 3 most-recent analyst ratings were released by Scotiabank, Needham, and Needham on December 11, 2024, December 5, 2024, and November 21, 2024, respectively. With an average price target of $39.67 between Scotiabank, Needham, and Needham, there's an implied 49.52% upside for NewAmsterdam Pharma Co NV from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for NewAmsterdam Pharma (NASDAQ:NAMS) was reported by Scotiabank on December 11, 2024. The analyst firm set a price target for $47.00 expecting NAMS to rise to within 12 months (a possible 77.16% upside). 16 analyst firms have reported ratings in the last year.
The latest analyst rating for NewAmsterdam Pharma (NASDAQ:NAMS) was provided by Scotiabank, and NewAmsterdam Pharma maintained their sector outperform rating.
There is no last upgrade for NewAmsterdam Pharma
There is no last downgrade for NewAmsterdam Pharma.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NewAmsterdam Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NewAmsterdam Pharma was filed on December 11, 2024 so you should expect the next rating to be made available sometime around December 11, 2025.
While ratings are subjective and will change, the latest NewAmsterdam Pharma (NAMS) rating was a maintained with a price target of $35.00 to $47.00. The current price NewAmsterdam Pharma (NAMS) is trading at is $26.53, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.